IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

INAB 11.05.2024

Full Press ReleaseSEC FilingsOur INAB Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Biotech Showcase 2025
  • 01.13.2025 - IN8bio Corporate Presentation - January 2025
  • 01.06.2025 - IN8bio to Present at Biotech Showcase 2025 in San Francisco

Recent Filings

  • 12.23.2024 - 4 Statement of changes in beneficial ownership of securities

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) --IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming poster presentation at the 66thAmerican Society of Hematology (ASH) Annual Meeting and Exposition, being hosted December 7 – 10, 2024 in San Diego, CA.

Details for the ASH 2024 presentation are as follows:

Title: INB-100: Pilot Study of Donor Derived, ex-vivo Expanded/Activated Gamma-Delta T cell Infusion Following Haploidentical Hematopoietic Stem-Cell Transplantation and Post-Transplant Cyclophosphamide
Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center
Abstract#: 4823
Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
Date and Time: Monday, December 9, 2024, 6:00 PM - 8:00 PM PDT

The abstract will be available online and can be accessed via the conference websites atASH Annual Meeting Abstracts. Reprints of the poster will also be accessible on theEvents & Presentationspage of IN8bio’s website following the presentations.

About IN8bioIN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogenic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visitwww.IN8bio.com.

Investors & Company Contacts:Glenn Schulman, PharmD, MPH203.494.7411gdschulman@IN8bio.com

Patrick McCallIN8bio, Inc.646.933.5603pfmccall@IN8bio.com

Media Contact:Kimberly HaKKH Advisors917.291.5744kimberly.ha@kkhadvisors.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com